Table 1.
Baseline patient characteristics, from 2014 to 2019
| Characteristics | 2014-2019 cohort |
|
|---|---|---|
| N | (%) | |
| Total number of patients | 110 | (100) |
| Demographics | ||
| Sex | ||
| Male | 78 | (71) |
| Female | 32 | (29) |
| Age, y | ||
| Median (IQR) | 73 (67-78) | |
| ≤65 | 22 | (20) |
| >65 | 88 | (80) |
| Blood counts, median (IQR) | ||
| Hb, g/dL∗ | 11.0 (9.0-12.4) | |
| Platelets, ×109/L∗ | 150 (95-273) | |
| Neutrophils, ×109/L† | 31.8 (18.6-60) | |
| Monocytosis (>1 × 109/L)∗ | 59 | (54) |
| Blasts, %‡ | 1 (1-4) | |
| Bone marrow features | ||
| Blast data available, n/N (%) | 93/110 (85%) | |
| Median (IQR), % | 2 (1-4) | |
| <5% | 72 | (77) |
| ≥5% | 21 | (23) |
| Fibrosis data available, n/N (%) | 87/110 (79%) | |
| Fibrosis present§ | 66 | (76) |
| Cytogenetics | ||
| Available | 98 | (89) |
| Normal karyotype | 83 | (85) |
| Abnormal karyotype‖ | 15 | (15) |
| Trisomy‖ | 10 | (10) |
| Molecular genetics | ||
| Available | 101 | (92) |
| ASXL1 mutation | 22 | (22) |
| SETBP1 mutation | 18 | (18) |
| SRSF2 mutation | 12 | (12) |
| CSFR3 mutation | 12 | (12) |
| JAK2 mutation | 9 | (9) |
| TET2 mutation | 8 | (8) |
| RUNX1 mutation | 6 | (6) |
| EZH2 mutation | 3 | (3) |
| Other mutations¶ | 8 | (8) |
| Number of mutations | ||
| No mutations | 52 | (51) |
| One mutation | 22 | (22) |
| Two mutations | 11 | (11) |
| Three or more mutations | 16 | (16) |
| First-line treatment | ||
| BSC only | 33 | (30) |
| Antineoplastic therapy without alloSCT | 62 | (56) |
| Antineoplastic therapy with alloSCT | 15 | (14) |
| Death during follow-up | 92 | (84) |
| Median follow-up, mo (IQR) | 16.8 (9.4-33.1) | |
alloSCT, allogeneic stem cell transplantation.
Missing in 1 patient.
Missing in 13 patients.
Missing in 18 patients.
Fibrosis data: 21 (19%) patients had no bone marrow fibrosis. 47 had grade 1 (42%), 18 had grade 2 (16%), 1 had grade 3 (1%), and 23 had an unknown grade (21%).
Abnormal karyotype includes 10 trisomies (ie, +8 [n = 6], +13 [n = 2], +21 [n = 1], and add(10p) [n = 1]). There remaining 5 patients had either a −20, -Y, del(13p), der(5p), or t(16;17). One patient had 2 abnormalities: add (10p) and i(17q). Notably, none of the patients had a complex karyotype.
Includes patients with the following mutations: CALR (n = 1), DNMT3A (n = 1), KIT (n = 2), CEPBA (n = 1), NPM1 (n = 1), IDH2 (n = 1), ETNK1 (n = 1), and KRAS/NRAS mutation (n = 2). Notably, a patient can harbor several mutations.